Kidney Transplant Clinical Trial
Official title:
Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy
Mesenchymal Stem Cell (MSC) have been shown to have immunosuppressive and repairing properties. the investigators will infuse expanded MSC into patients who develop Chronic Allograft Nephropathy. The purpose of this study is to find out MSC is more effective in preventing organ rejection and maintaining kidney function.
Kidney transplantation is a common procedure in hospitals, but organ rejection and chronic
nephrotoxicity are potential problems for the patient. Approximately ninety percent of the
protocol biopsies of renal allografts, performed at 18 months post transplantation, show
histological lesions of chronic calcineurin nephrotoxicity. Mesenchymal Stem Cell (MSC) has
been shown to have immunosuppressive and repairing properties. Some patient in this study
will also receive two infusions of expanded MSC. This study will evaluate the safety and
effectiveness of MSC infusions in patients .
This study will last 2 years. Participants will be randomly assigned to receive either the
full immunosuppressive therapy and MSC infusions (Group 1) or immunosuppressive therapy
alone (Group 2). Patients will undergo MSC infusions at the start of the study on Day 0. One
year post- infusions, patients will be evaluated. At Months 12 participants will undergo
kidney biopsies. Blood collection will occur at regular intervals, Serum creatinine and the
estimated creatinine clearance will be monthly recorded. The transplanted kidney function
will be evaluated.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04087720 -
Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant
|
Phase 4 | |
| Completed |
NCT03749356 -
Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients
|
Phase 4 | |
| Withdrawn |
NCT05811468 -
Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
|
||
| Completed |
NCT03527238 -
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
|
Phase 2 | |
| Completed |
NCT00498576 -
Melatonin and Adiponectin in Hypertensive Kidney Transplant
|
N/A | |
| Completed |
NCT00642655 -
Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT00374400 -
The Paired Donation Consortium Paired Donation Program
|
N/A | |
| Completed |
NCT01710033 -
A Study Of CP-690,550 In Stable Kidney Transplant Patients
|
Phase 1 | |
| Completed |
NCT00205257 -
Prediction of Acute Rejection in Renal Transplant
|
Phase 1 | |
| Completed |
NCT02711826 -
Treg Therapy in Subclinical Inflammation in Kidney Transplantation
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03978494 -
Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.
|
Phase 1 | |
| Completed |
NCT03837522 -
Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies
|
N/A | |
| Not yet recruiting |
NCT06025240 -
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
|
||
| Completed |
NCT05029310 -
Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients
|
Phase 4 | |
| Completed |
NCT03644485 -
Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients
|
Phase 4 | |
| Active, not recruiting |
NCT02409901 -
Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients
|
N/A | |
| Completed |
NCT01047410 -
ACtive Care After Transplantation, the ACT Study
|
N/A | |
| Completed |
NCT00940940 -
Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation
|
Phase 4 | |
| Completed |
NCT00270712 -
A Study of Factors That Affect Long-Term Kidney Transplant Function
|
||
| Completed |
NCT00217126 -
The Study of Long-term Deterioration of Kidney Transplants.
|
Phase 4 |